China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1 Expedited approval as an initial treatment in China follows U.S. accelerated approval for HERNEXEOS® (zongertinib tablets) in February, reflecting high recognition of urgency and unmet clinical need2 This […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.